No FCA Claim from ‘Off-Label’ Marketing

A pharmaceutical company employee has not stated a claim under the False Claims Act with general allegations that the company’s marketing of its “off-label” prescriptions and unnecessarily high-dose prescriptions of the company’s Kapidex drug necessarily meant that false claims for reimbursement had been submitted to federally sponsored health care plans; the 4th Circuit affirms dismissal ...